Literature DB >> 18784130

Mechanisms of vascular damage in SSc--implications for vascular treatment strategies.

S Guiducci1, O Distler, J H W Distler, M Matucci-Cerinic.   

Abstract

Vascular abnormalities are a major component of SSc, but little is known about the events or mechanisms that initiate vascular injury and prevent its repair. In SSc, angiogenesis is incomplete or lacking despite the increased expression of a large array of pro-angiogenic factors such as VEGF. Conflicting results have recently been published concerning the presence and role of vasculogenesis and circulating endothelial progenitor cells in SSc. It remains to be established if these endothelial progenitor cells are a marker of endothelial disease or a cause of insufficient vascular repair. Human mesenchymal stem cells (MSCs) may be an alternative source for endothelial progenitor cells, and it has been observed that the angiogenic potential of endothelial-like MSCs is reduced. Other mechanisms of vascular damage include oxidative stress and factors released from activated platelets. In addition, growth factors such as ET-1 and PDGF induce proliferation of vascular smooth muscle cells resulting in intimal thickening. For the development of new therapeutic strategies, it is important to realize that the different vascular pathologies--uncompensated loss of capillaries on one hand and vascular remodelling with a proliferative vasculopathy on the other--might require different treatment approaches.

Entities:  

Mesh:

Year:  2008        PMID: 18784130     DOI: 10.1093/rheumatology/ken267

Source DB:  PubMed          Journal:  Rheumatology (Oxford)        ISSN: 1462-0324            Impact factor:   7.580


  29 in total

1.  Vascular leak is a central feature in the pathogenesis of systemic sclerosis.

Authors:  Tracy M Frech; Monica P Revelo; Stavros G Drakos; Maureen A Murtaugh; Boaz A Markewitz; Allen D Sawitzke; Dean Y Li
Journal:  J Rheumatol       Date:  2012-06-01       Impact factor: 4.666

2.  Serum Soluble CD163 and its association with various disease parameters in patients with systemic sclerosis.

Authors:  Waleed Ahmed Salah Eldeen Hassan; Eman Abd Elaleem Baraka; Basant Mohammed Elnady; Tahany Mahmoud Gouda; Nehad Fouad
Journal:  Eur J Rheumatol       Date:  2016-09-01

3.  Impaired angiogenesis as a feature of digital ulcers in systemic sclerosis.

Authors:  Ivone Silva; Cristiana Almeida; Andreia Teixeira; José Oliveira; Carlos Vasconcelos
Journal:  Clin Rheumatol       Date:  2016-02-26       Impact factor: 2.980

Review 4.  Infection and autoimmune disease.

Authors:  Asli Gamze Sener; Ilhan Afsar
Journal:  Rheumatol Int       Date:  2012-07-19       Impact factor: 2.631

5.  Increased finger skin vasoreactivity and stimulated vasomotion associated with simvastatin therapy in systemic sclerosis hypercholesterolemic patients.

Authors:  Marco Rossi; Laura Bazzichi; Lorenzo Ghiadoni; Ilaria Mencaroni; Ferdinando Franzoni; Stefano Bombardieri
Journal:  Rheumatol Int       Date:  2011-11-06       Impact factor: 2.631

Review 6.  Pharmacotherapy of systemic sclerosis.

Authors:  Arnold E Postlethwaite; L Jeff Harris; Syed H Raza; Swapna Kodura; Titilola Akhigbe
Journal:  Expert Opin Pharmacother       Date:  2010-04       Impact factor: 3.889

7.  Circulating angiopoietin and Tie-2 levels in systemic sclerosis.

Authors:  James V Dunne; Kevin J Keen; Stephan F Van Eeden
Journal:  Rheumatol Int       Date:  2012-03-30       Impact factor: 2.631

8.  Systemic sclerosis induces pronounced peripheral vascular dysfunction characterized by blunted peripheral vasoreactivity and endothelial dysfunction.

Authors:  Tracy Frech; Ashley E Walker; Zachary Barrett-O'Keefe; Paul N Hopkins; Russell S Richardson; D Walter Wray; Anthony J Donato
Journal:  Clin Rheumatol       Date:  2014-12-16       Impact factor: 2.980

Review 9.  Engineering dextran-based scaffolds for drug delivery and tissue repair.

Authors:  Guoming Sun; Jeremy J Mao
Journal:  Nanomedicine (Lond)       Date:  2012-11       Impact factor: 5.307

Review 10.  [Scleroderma].

Authors:  O Distler; S Gay
Journal:  Internist (Berl)       Date:  2010-01       Impact factor: 0.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.